Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease
- 作者: Taranova M.1, Milovanova L.1, Kozlovskaya(Lysenko) L.1, Milovanova S.1, Androsova T.1, Zubacheva D.1, Lebedeva M.1, Dobrosmyslov I.1, Kozlov V.1, Kuchieva A.1, Li O.1, Reshetnikov V.1
-
隶属关系:
- Sechenov First Moscow State Medical University of the Ministry (Sechenov University)
- 期: 卷 91, 编号 6 (2019)
- 页面: 85-92
- 栏目: Articles
- URL: https://journals.rcsi.science/0040-3660/article/view/59006
- DOI: https://doi.org/10.26442/00403660.2019.06.000253
- ID: 59006
如何引用文章
全文:
详细
作者简介
M. Taranova
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии; ORCID: 0000-0002-7363-6195 Moscow, Russia
L. Milovanova
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)
Email: Ludm.milovanova@gmail.com
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии; тел.: +7(916)164-14-00; e-mail: Ludm.milovanova@gmail.com; ORCID: 0000-0002-5599-0350 Moscow, Russia
L. Kozlovskaya(Lysenko)
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии; ORCID: 0000-0002-1166-7308 Moscow, Russia
S. Milovanova
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)д.м.н., в.н.с. НИО здоровьесберегающих технологий Научно-технологического парка биомедицины; ORCID: 0000-0002-2687-6161 Moscow, Russia
T. Androsova
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии; ORCID: 0000-0002-9951-126X Moscow, Russia
D. Zubacheva
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)ординатор 1-го года кафедры внутренних, профессиональных болезней и ревматологии; ORCID 0000-0001-8020-7041 Moscow, Russia
M. Lebedeva
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии; ORCID: 0000-0002-5923-1837 Moscow, Russia
I. Dobrosmyslov
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)к.м.н., зав. отделением «Искусственная почка» Клиники нефрологии и внутренних болезней Moscow, Russia
V. Kozlov
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)доц. каф. общественного здоровья и организации здравоохранения; ORCID: 0000-0002-2389-3820 Moscow, Russia
A. Kuchieva
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)врач отделения нефрологии и гемодиализа; ORCID: 0000-0002-8360-7734 Moscow, Russia
O. Li
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)ассистент каф. внутренних, профессиональных болезней и ревматологии, врач отделения нефрологии и гемодиализа; ORCID: 0000-0003-1739-677Х Moscow, Russia
V. Reshetnikov
Sechenov First Moscow State Medical University of the Ministry (Sechenov University)д.м.н., проф. каф. общественного здоровья и организации здравоохранения; ORCID 0000-0002-2987-7995 Moscow, Russia
参考
- Couser W.G, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258-70. doi: 10.1038/ki.2011.368
- Levin A, Stevens P.E, Bilous R.W, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;3:1-150. doi: 10.1038/kisup.2012.73
- Hu M.C, Shiizaki K, Kuroo M, et al. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013;75:503-33. doi: 10.1146/annurev-physiol-030212-183727
- Scialla J.J, Xie H, Rahman M, et al. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD, the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. J Am Soc Nephrol. 2014;25(2):349-60. doi: 10.1681/ASN.2013050465
- Milovanova L, Fomin V.V, Lysenko (Kozlovskaya) L.V, et al. Disorders in the System of Mineral and Bone Metabolism Regulators - FGF-23, Klotho and Sclerostin - in Chronic Kidney Disease: Clinical Significance and Possibilities for Correction. Chapter in the book “Chronic Kidney Disease”. INTECH. 2017. ISBN 978-953-51-5463-1. http// dx.doi.org/10.5772/66239
- Kardami E. Fibroblast growth factor 23 isoforms and cardiac hypertrophy. Cardiovasc Res. 2004;63(3):458-66. doi: 0.1016/j.cardiores.2004.04.024
- Hu M.C, Kuroo M, Moe O.W. Klotho and Chronic Kidney Disease. Contrib Nephrol. 2013;180:47-63. doi: 10.1159/000346778
- Kuroo M. Klotho in chronic kidney disease - What's new? Nephrol Dialysis Transplant. 2009;24(6):1705-8. doi: 10.1093/ndt/gfp069
- Hu M.C, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. Am J Soc Nephrol. 2011;22(1):124-36. doi: 10.1681/ASN.2009121311
- Hu M.C, Kuroo M, Moe O.W. Renal and Extra-Renal Actions of Klotho. Semin Nephrol. 2013;33(2):118-29. doi: 10.1016/j.semnephrol.2012.12.013
- Milovanova L.Y, Milovanov Y.S, Kozlovskaya L.V. Nephro - cardioprotective role of the circulating forms of the KLOTHO protein in chronic kidney disease. Clin Nephrol. 2013;3:7-10. doi: https://doi.org/10.18454/IRJ.2016.51.074
- Chen S, Huang H, Wu B, et al. Cardiac Troponin I in Non - Acute Coronary Syndrome Patients with Chronic Kidney Disease. PLoS One. 2013;8(12):12-9. doi: 10.1371/journal.pone.0082752
- Abbas N.A, John R.I, Webb M.C, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem. 2005;51(11):2059-66.
- Cheng H-M, Chuang S-Y, Sung S-H, et al. Derivation and validation of Diagnostic thresholds for Central Blood Pressure Measurements based on Long-Term Cardiovascular Risks. J Amer Coll Cardiol. 2013; 62(19):1780-7. doi: 10.1016/j.jacc.2013.06.029
- Mancia G, De Backer G, Dominiczak A, et al. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34: 34 (28): 2159-2219. doi: 10.1093/eurheartj/eht151
- Ермоленко В.М., Волгина Г.В., Добронравов В.А. и др. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010). Нефрология и диализ. 2011;13(1):33-51.
- Милягин В.А., Комиссаров В.Б. Современные методы определения жесткости сосудов. Артериальная гипертензия. 2010;16(2):134-143. doi: https://doi.org/10.18705/1607-419X-2010--2-
- Townsend R.R, Wilkinson I.B, Schiffrin E.L, et al. American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement from the American Heart Association. J Hypertension. 2015;66(3):698-722.
- Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике (конгресс РКО, 2015). Кардиоваскулярная терапия и профилактика. 2016;15(2):4-19. doi: 10.15829/1728-8800-2016-2-4-19
- Mc Murray J.J, Uno H, Jarolim P, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin - alfa) Therapy (TREAT). Am Heart J. 2011;162(4):748-55. doi: 10.1016/j.ahj.2011.07.016
- Smith K, de Filippi C, Isakov T, et al. Fibroblast Growth Factor 23, High-Sensitivity Cardiac Troponin, and Left Ventricular Hypertrophy in CKD. Am J Kidney Dis. 2013;61(1):67-73. doi: 10.1053/j.ajkd.2012.06.022
- Faul C, Amaral A.P, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-408. doi: 10.1172/JCI46122
- Shinichiro N, Yoshitaka I, Takaharu Y, et al. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med. 2017;4:10. doi: 10.3389/fcvm.2017.00010
- Scialla J.J, Lau W.L, Reilly M.P, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013;83:1159-68. doi: 10.1038/ki.2013.3
- Marthi A, Donovan K, Haynes R, et al. Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. JASN. 2018;29(7):2015-27; doi: 10.1681/ASN.2017121334
- Sze J, Mooney J, Barzi F. Cardiac troponin and its relationship to cardiovascular outcomes in community populations - a systematic review and meta - analysis. Heart Lung Circ. 2016;25:217-28. doi: 10.1016/j.hlc.2015.09.001
- Jacobs L.H, van de Kerkhof J, Mingels A.M, et al. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem. 2009;46:283-90. doi: 10.1258/acb.2009.008197
- Stacy S.R, Suarez-Cuervo C, Berger Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: a systematic review. Ann Intern Med. 2014;161:502-12. doi: 10.7326/M14-0746
- Bansal N, Hyre Anderson A, Yang W, et al. High - sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the chronic renal insufficiency cohort (CRIC) study. J Am Soc Nephrol. 2015;26:946-56. doi: 10.1681/ASN.2014010108